Research programme: P2X receptor antagonists - Abbvie

Drug Profile

Research programme: P2X receptor antagonists - Abbvie

Alternative Names: A-740003

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Abbott Laboratories
  • Developer AbbVie
  • Class Hydrazines; Tetrazoles
  • Mechanism of Action Purinergic P2X7 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Inflammation; Mood disorders; Pain

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Inflammation in USA
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Pain in USA
  • 04 Nov 2017 No recent reports of development identified for research development in Mood disorders in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top